Instituto do Cancer do Estado de São Paulo
icesp.org.brLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
90
Active
22
Phase 3
5
Total enrollment
11,487
Pipeline matrix
Showing 21 of 21 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Pembrolizumab | — | — | — | — | — | 2 | |
| Nivolumab | — | — | — | — | — | 2 | |
| Realgar-Indigo Naturalis Formulation | — | — | — | — | — | 1 | |
| FOLFIRINOX | — | — | — | — | — | 1 | |
| Regorafenib Oral Product | — | — | — | — | — | 1 | |
| Encapsulated amisulpride 50 mg | — | — | — | — | — | 1 | |
| Encapsulated placebo | — | — | — | — | — | 1 | |
| Bortezomib | — | — | — | — | — | 1 | |
| Docetaxel 50mg/m2 | — | — | — | — | — | 1 | |
| Docetaxel 60mg/m2 | — | — | — | — | — | 1 | |
| Docetaxel 75 mg/m² | — | — | — | — | — | 1 | |
| Prednisone | — | — | — | — | 2 | ||
| Vincristin | — | — | — | — | — | 1 | |
| Daunorubicin | — | — | — | — | — | 1 | |
| Peg-asparaginase | — | — | — | — | — | 1 | |
| Intrathecal Suspension | — | — | — | — | — | 1 | |
| Cyclophosphamide | — | — | — | — | — | 1 | |
| Cytarabine | — | — | — | — | — | 1 | |
| Mercaptopurine | — | — | — | — | — | 1 | |
| Methotrexate | — | — | — | — | — | 1 | |
| Doxorubicin | — | — | — | — | — | 1 |
Next readouts
- 2026-07
- 2026-09
- 2026-11-15
- 2026-12
- 2026-12-30
- 2027-01-30
- 2027-03-29
- 2028-06
- 2028-08
- 2028-11
Top conditions
- Breast Cancer9
- Prostate Cancer6
- Gastric Cancer5
- Rectal Cancer5
- Cancer4
- Head and Neck Cancer3
- Postoperative Nausea3
- Postoperative Nausea and Vomiting3
Frequently asked questions about Instituto do Cancer do Estado de São Paulo
- How many clinical trials does Instituto do Cancer do Estado de São Paulo have on ClinicalTrials.gov?
- Instituto do Cancer do Estado de São Paulo is listed as the lead sponsor on 90 clinical trials in ClinicalTrials.gov, 22 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Instituto do Cancer do Estado de São Paulo's trials are in Phase 3?
- 5 of Instituto do Cancer do Estado de São Paulo's trials are in Phase 3, spread across 21 active drug programs.
- What therapeutic areas does Instituto do Cancer do Estado de São Paulo focus on?
- Instituto do Cancer do Estado de São Paulo's most-studied conditions on ClinicalTrials.gov are Breast Cancer, Prostate Cancer, Gastric Cancer, Rectal Cancer, Cancer.
- When are Instituto do Cancer do Estado de São Paulo's next clinical trial readouts?
- Instituto do Cancer do Estado de São Paulo has 10 upcoming primary-completion readouts tracked here; the soonest is “Agnostic Therapy in Rare Solid Tumors”, expected around 2026-07.